[關(guān)鍵詞]
[摘要]
目的 探討知柏地黃丸聯(lián)合亮丙瑞林治療女童中樞性性早熟的效果分析。方法 選取2015年11月-2017年11月西安市兒童醫(yī)院收治的中樞性性早熟女童61例,采用隨機(jī)數(shù)字表法將患兒分為兩組,對照組患兒給予亮丙瑞林,觀察組在對照組的基礎(chǔ)上給予知柏地黃丸,比較兩組患兒的臨床治療效果及骨齡指數(shù),B超觀察兩組患兒的乳房轉(zhuǎn)歸情況、子宮容積、卵巢容積和卵泡直徑變化趨勢。結(jié)果 兩組患兒治療的總有效率比較無統(tǒng)計(jì)學(xué)差異;治療前后兩組患兒的骨齡指數(shù)比較及組間比較無統(tǒng)計(jì)學(xué)差異。觀察組患兒乳房轉(zhuǎn)歸有效率顯著高于對照組(P<0.05)。治療后兩組患兒的子宮容積、卵巢容積和卵泡直徑均顯著下降(P<0.05),且觀察組顯著低于對照組(P<0.05)。兩組患兒治療期間均未出現(xiàn)不良反應(yīng),且肝腎功能檢查均在正常范圍內(nèi)。結(jié)論 知柏地黃丸聯(lián)合亮丙瑞林治療女童中樞性性早熟的乳房轉(zhuǎn)歸有效率較高,并可顯著改善患兒的子宮容積、卵巢容積和卵泡直徑,延緩且不良反應(yīng)較少,安全性較高。
[Key word]
[Abstract]
Objective To investigate the effect of Zhibai Dihuang Pill combined with leuprorelin in the treatment of central precocious puberty in girls.Methods 61 cases of central precocious puberty girls were selected from November 2015 to November 2017 in our hospital, and were divided into two groups by random number table method. The control group was given leuprorelin, and the observation group was given Zhibai Dihuang Pills on the basis of the control group. The clinical therapeutic effect and bone age index of the two groups were compared, and the breast outcome, uterine volume, ovarian volume and follicular diameter of the two groups were observed by ultrasound. Results There was no significant difference in the total effective rate between the two groups. There was no significant difference in bone age index between the two groups before and after treatment. The breast conversion efficiency of the observation group was significantly higher than that of the control group (P<0.05). There were no significant differences in uterine volume, ovarian volume and follicular diameter between the two groups before treatment. After treatment, both groups were significantly decreased, and the observation group was significantly lower than the control group (P<0.05). No adverse reactions were found in the two groups during treatment, and the liver and kidney function tests were within the normal range.Conclusion Zhibai Dihuang Pill combined with leuprorelin in the treatment of girls with central precocious puberty has a higher breast conversion efficiency, and can significantly improve the uterine volume, ovary volume and follicular diameter of the children, delay and less adverse reactions, higher safety.
[中圖分類號]
[基金項(xiàng)目]
陜西省社會發(fā)展科技攻關(guān)項(xiàng)目(2015SF215)